Erythropoietin Treatment in Patients With Systolic Left Ventricular Dysfunction, Mild Anemia and Normal Renal Function

Heart Failure Clinical Trial

Official title:

Phase 4 Study on the Efficacy of Erythropoietin Treatment in Patients With Systolic Left Ventricular Dysfunction, Mild Anemia and Normal Renal Function

Clinical Trial Details — Status: Not yet recruiting

Administrative data

• NCT number: NCT00418119
• Other study ID #: 4273
• Status: Not yet recruiting
• Phase: Phase 4
• First received: January 2, 2007
• Last updated: January 3, 2007
• Start date: January 2007
• Est. completion date: January 2008

Study information

• Verified date: December 2006
• Source: Rabin Medical Center
• Contact: Tuvia Ben Gal, MD
• Phone: 972-522757616
• Email: bengalt[@]clalit.org.il
• Is FDA regulated: No
• Health authority: Israel: Ethics Commission
• Study type: Interventional

Clinical Trial Summary

Erythropoietin Treatment in Patients with systolic left ventricular dysfunction, mild anemia and normal renal function

Recruitment information / eligibility

• Status: Not yet recruiting
• Enrollment: 10
• Est. completion date: January 2008
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Ischemic heart disease

• Systolic lv dysfunction

• Mild anemia

• Normal renal function

• Stable condition

Exclusion Criteria:

• Pregnancy

• Unstable condition

• Under 18 years old

Study Design

Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

• Heart Failure
• Ventricular Dysfunction
• Ventricular Dysfunction, Left

Intervention

Drug:
• erythropoietin

Locations

Country	Name	City	State
Israel	Cardiology Department, Rabin Medical Center	Petah Tikva

Sponsors (1)

Lead Sponsor	Collaborator
Rabin Medical Center

Country where clinical trial is conducted

Israel,